Some real-world cohorts and pooled analyses report greater weight loss among women treated with GLP-1 RAs than among men, though findings are not entirely consistent, and effect sizes vary by agent and population studied (Rivera et al., 2024
Although Wegovy reported greater global annual sales than Zepbound in 2024, (~$8.4B USD), global annual sales for Wegovy (~$22B USD) are forecast to be similar but lower than Zepbound (~$26B-$28B USD) by 2031
What delivery methods are available and how do they differ
Pack size and paracetamol overdose: 16 years later
For this reason, however, a deficiency only becomes symptomatic years later
To discuss your treatment options-whether you are comparing semaglutide vs lifestyle interventions , exploring the pros and cons of medication, or considering your next steps in the GLP1 weight loss comparison -we are here to help